Navigation Links
Statin Use Doesn't Inhibit Lymphoma Drug Therapy
Date:12/9/2008

Cholesterol-lowering meds may actually help patients on rituximab, study suggests

TUESDAY, Dec. 9 (HealthDay News) -- Cholesterol-lowering statin drugs don't interfere with rituximab, a medication used to treat lymphomas, say Mayo Clinic researchers, who also found that statins may actually slow progression of some kinds of lymphomas.

Rituximab is a monoclonal antibody often used alone or in conjunction with chemotherapy to treat lymphomas -- cancers of the lymph system. A study published earlier this year suggested that statins may inhibit rituximab's ability to bind to CD20, a protein found on lymphoma cells.

"That finding raised questions about maintaining or stopping cholesterol treatment with statins for patients with lymphoma," Mayo hematologist Dr. Grzegorz Nowakowski said in a clinic news release. "One in five lymphoma patients take cholesterol-lowering statins. This corresponds to the potential for thousands of patients at risk of getting less or ineffective treatment due to statin interference with therapy."

To clarify the issue, the Mayo team studied 228 patients with aggressive diffuse large B-cell lymphoma and 293 patients with slowly progressive follicular lymphoma. Twenty-two percent of the patients with diffuse large B-cell lymphoma and 19 percent of patients with follicular lymphoma were taking statins when they began treatment for their lymphoma.

Statin use didn't influence outcomes for patients with diffuse large B-cell lymphoma. Among the patients with follicular lymphoma, those taking statins actually had better outcomes. At two years, 80 percent of follicular lymphoma patients taking statins had no progression or re-treatment for their cancer, compared with 69 percent of patients not taking statins. This positive effect was observed regardless of the type of treatment: observation only; rituximab alone; or rituximab in combination with chemotherapy.

The study was expected to be presented Monday at the annual meeting of the American Society of Hematology, in San Francisco.

"These results can provide reassurance to oncologists and their patients that statins will not reduce the effectiveness of rituximab (brand name Rituxan) and may in fact improve outcomes of some patients with lymphomas," Nowakowski said.

More information

The Lymphoma Research Foundation has more about lymphoma.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Dec. 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Continued Statin Use Boosts Post-Stroke Outcomes
2. Stopping Statins After Stroke Doubles Death Risk
3. Research to shed new light on how statins benefit heart patients
4. A New Study Links High Volume Pain Pumps with the Devastating and Painful Loss of Cartilage Following Arthroscopic Shoulder Surgery
5. Statin Benefits Persist After Treatment Stops
6. Statins reduce loss of function, keeping old lungs young - even in smokers
7. Better Prostate Cancer Survival for Men Taking Statins
8. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
9. Congress called on to replace devastating cuts in Medicare reimbursements by ACP
10. Statins After Bypass Lower Stroke Risk
11. Burn injuries take devastating toll on nations children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Statin Use Doesn't  Inhibit  Lymphoma Drug Therapy
(Date:7/24/2017)... ... 2017 , ... SignatureCare Emergency Center is looking to award their ... to a deserving student. Get your applications in now as the deadline is ... Castillo who is a nursing student at Prairie View A&M University with a 3.45 ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... Oakland, California effectively destroyed the construction site and threatened numerous homes and businesses ... 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection ...
(Date:7/24/2017)... CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... and financial organizations, today announced it has partnered with WALLIX to expand ... Special Publication 800-171 . , There are a number of ways to address the ...
(Date:7/24/2017)... California (PRWEB) , ... July 24, 2017 , ... ... of autologous fat (adipose) transfer systems announces the issuance of United States Patent ... patent) for its adipose filtration technology. The '398 and '324 patents cover ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... sleep management solution focused on delivering end-to-end sleep health care at scale, ... Recent literature shows that adherence rates for positive airway pressure (PAP) therapy, the ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... and EDMONTON, Alberta , July ... and the University of Alberta in ... in Nature,s partner journal, Schizophrenia 1 , demonstrating ... instances of schizophrenia with 74% accuracy. This retrospective ... of specific symptoms in schizophrenia patients with significant ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc (NASDAQ: ... a comprehensive review of its manufacturing network, the Company ... distribution facilities in Huntsville, Alabama . ... place over the next 12 to 18 months. The ... by declining volumes of commoditized products and these restructuring ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) ... Gavras , M.D., following today,s Institute for Clinical and Economic ... on the effectiveness and value of abuse-deterrent formulations (ADF) ... the policy roundtable at the meeting. ... a material cost benefit to the use of abuse-deterrent formulations ...
Breaking Medicine Technology: